Why the study?
Does MS-551 prevent fatal ventricular fibrillation in canine coronary ligation-reperfusion models compared to d-sotalol?
Does MS-551 prevent fatal ventricular fibrillation in canine coronary ligation-reperfusion models compared to d-sotalol?
MS-551 and d-sotalol exhibit different antiarrhythmic and proarrhythmic profiles in canine reperfusion models despite similar QTc prolonging properties.
No takes yet. Share an insight, caveat, or question.
Raises torsades risk despite VF suppression in canine reperfusion; leaves open net benefit versus d-sotalol for clinical translation.
Hashimoto et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: